BioLife Solutions, Inc. (BLFS)
| Market Cap | 1.01B |
| Revenue (ttm) | 96.21M |
| Net Income (ttm) | -4.60M |
| Shares Out | 48.30M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | 163.28 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 324,216 |
| Open | 21.41 |
| Previous Close | 21.41 |
| Day's Range | 20.73 - 21.42 |
| 52-Week Range | 17.86 - 29.62 |
| Beta | 2.00 |
| Analysts | Strong Buy |
| Price Target | 32.00 (+53.11%) |
| Earnings Date | May 7, 2026 |
About BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduc... [Read more]
Financial Performance
In 2025, BioLife Solutions's revenue was $96.21 million, an increase of 28.89% compared to the previous year's $74.65 million. Losses were -$4.60 million, -77.23% less than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for BLFS stock is "Strong Buy" and the 12-month stock price target is $32.0.
News
BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mar...
BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase
Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading develop...
BioLife Solutions Earnings Call Transcript: Q4 2025
Delivered 29% revenue growth and margin expansion in 2025, driven by commercial BPM customers and portfolio optimization. 2026 guidance calls for 17–20% revenue growth, positive GAAP net income, and continued margin improvement, with growth led by commercial demand.
BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
Fourth quarter 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year; Full year 2025 revenue of $96.2 million, up 29% year-over-year GAAP gross margin of 63% and non-GAAP ad...
BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026
BOTHELL, Wash., Feb. 17, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mark...
BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market
BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, a...
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2025 Unaudited Revenue from Continuing Operations
Fourth quarter unaudited revenue from continuing operations of $24.8 million increased 20% from the prior year fourth quarter Full year unaudited revenue from continuing operations of $96.2 million ex...
BioLife Solutions Unveils the Aby J. Mathew Center for Biopreservation Excellence
New conference and laboratory facility to showcase the company's product portfolio and serve as a research and training hub to advance biopreservation and cell processing innovation BOTHELL, Wash. , N...
BioLife Solutions to Participate in Upcoming Investor Conferences in November and December 2025
BOTHELL, Wash. , Nov. 17, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) mark...
BioLife Solutions Earnings Call Transcript: Q3 2025
Q3 revenue grew 31% year-over-year, driven by strong cell processing sales and margin expansion. Full-year guidance was raised following the sale of the evo Cold Chain business, with commercial and late-stage clinical customers expected to drive future growth.
BioLife Solutions Reports Third Quarter 2025 Financial Results
Cell Processing revenue of $25.4 million, up 33% over Q3 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 64% GAAP net income of $0.6 million and non-GAAP adjusted EBITDA of $7.8 m...
BioLife Solutions to Report Third Quarter 2025 Financial Results and Business Update on November 6, 2025
BOTHELL, Wash. , Oct. 23, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mar...
BioLife Solutions Announces the Sale of its evo Cold Chain Logistics Subsidiary
BOTHELL, Wash. , Oct. 7, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene ther...
BioLife Solutions Earnings Call Transcript: Q2 2025
Q2 2025 saw 29% revenue growth, led by cell processing, and expanded adjusted EBITDA margin. Full-year guidance was raised, with strong visibility into second-half demand and continued investment in strategic growth initiatives.
BioLife Solutions Reports Second Quarter 2025 Financial Results
Cell Processing revenue of $23.0 million, up 28% over Q2 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million, inclusive of a non-cash $15.5 million ...
BioLife Solutions Makes Strategic Investment in Pluristyx
BOTHELL, Wash. , July 28, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mar...
BioLife Solutions to Report Second Quarter 2025 Financial Results and Business Update on August 7, 2025
BOTHELL, Wash. , July 24, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mar...
BioLife Solutions to Participate in Upcoming Investor Conferences in May and June 2025
BOTHELL, Wash. , May 14, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") mark...
BioLife Solutions Updates Earnings Call Information
BOTHELL, Wash. , May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell a...
BioLife Solutions Earnings Call Transcript: Q1 2025
Q1 2025 saw 30% revenue growth and significant EBITDA margin expansion, led by cell processing. Guidance for 2025 was reaffirmed, with Panthera acquisition bolstering R&D but not expected to contribute revenue this year. Balance sheet remains strong with $107.6M in cash.
BioLife Solutions Reports First Quarter 2025 Financial Results
Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 mil...
BioLife Solutions to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
BOTHELL, Wash. , April 30, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") ma...
BioLife Solutions Acquires PanTHERA CryoSolutions to Advance Leadership as a Pure Play Bioproduction Consumables Company
Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTH...
BioLife Solutions Appoints Cathy Coste as Director and Audit Committee Chair
BOTHELL, Wash. , March 18, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell...
BioLife Solutions Earnings Call Transcript: Q4 2024
2024 saw a strategic transformation with divestitures boosting margins and cash, while cell processing revenue hit record highs. 2025 guidance projects 16–20% revenue growth, margin expansion, and increased R&D, with growth driven by commercial therapy customers and cross-selling initiatives.